Clinical trial · Observational
Updates and Insights on HER2 in Breast Cancer in Sohag Governorate
Updates and Insights on Human Epidermal Growth Factor Receptor 2 (HER2) in Breast Cancer in Sohag Governorate
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors. * To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes * To access interobserval agreement in HER2 score interpretation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2 Status in Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Breast cancer female patients
- description
- Female patients with histopathologically confirmed breast cancer diagnosed at Sohag Oncology center during 2025-2026. Archived formalin-fixed paraffin-embedded tissue samples and pathology records will be retrospectively reviewed to evaluate HER2 status by immunohistochemistry (IHC)
Primary outcomes (1)
- measure
- HER2 status in breast cancer
- timeFrame
- 2025/2026
- description
- To evaluate the HER2 status among breast cancer patients diagnosed at Sohag Oncology center using immunohistochemistry (IHC) and, when indicated, in situ hybridization (ISH), and to describe the distribution of HER2 expression.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 26 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Breast cancer cases diagnosed during 2025 and 2026. * Cases with available HER2 immunohistochemical results. * Cases with sufficient tissue material for evaluation. * Cases with complete clinical and follow-up data. * Cases that were accessible for pathologic review Exclusion Criteria: * Cases with insufficient, destroyed, necrotic, or unavailable tissue blocks. * Cases with incomplete clinical information. * Cases lacking adequate immunohistochemical assessment. * Cases outside the study period
References
Publications (0)
Data not yet available